HCC | Clinical

COVID-19 Pandemic Delays Treatment for HCC, Says French Cancer Center Analysis

October 08, 2020

In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the coronavirus disease 2019 pandemic, according to the results of a study of 6 academic referral centers.

Expert Recognizes Expansion of HCC Treatment Options During Liver Cancer Awareness Month

October 07, 2020

In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.

Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC

October 06, 2020

Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.

In Light of Recently Approved Regimens, Sequencing Strategies Are Under Discussion in HCC

October 05, 2020

Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.

ILCA Data Reignite Interest in AFP as a Biomarker for HCC

October 04, 2020

Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.